Material World: AMSilk Secures Over $60M to Scale, Sealwool’s Biomimetic Twist

AMSilk Overview - AMSilk has transitioned to full-scale production, indicating strong commercial validation and readiness to meet market demand for biofabricated materials [1] - The company has installed dedicated production facilities at key industrial partners to manufacture its proprietary silk-based protein materials [1] Funding and Growth - AMSilk secured €52 million (approximately $61.1 million) in funding, which will be used to scale up production and establish a new industry for high-performance biotech materials [5] - The funding round was led by Athos, with participation from MIG Capital and Novo Holdings, combining $35.25 million in equity and $22.85 million in convertible bonds, reflecting strong investor confidence [4] Production Agreements and Strategy - AMSilk has entered into multi-year production agreements to establish a long-term basis for industrial output and supply reliability [2] - The company is focused on creating robust processes and resilient supply chains to deliver on its industrial commitments and scale its biomaterials for global markets [3]